Featured Research

from universities, journals, and other organizations

San Francisco Study Shows Antiretroviral Treatment Continues To Improve AIDS Survival

Date:
July 18, 2000
Source:
University Of California, San Francisco
Summary:
A study from the San Francisco Department of Public Health and University of California, San Francisco found that treatment with potent antiretroviral therapy continues to significantly improve how long AIDS patients survive with the disease. The findings do not support concerns voiced among some researchers that such therapy might lose its effectiveness over time.

A study from the San Francisco Department of Public Health and University of California, San Francisco found that treatment with potent antiretroviral therapy continues to significantly improve how long AIDS patients survive with the disease. The findings do not support concerns voiced among some researchers that such therapy might lose its effectiveness over time.

"Our data show a very significant survival benefit from use of antiretroviral therapy, particularly when it includes a protease inhibitor," said Sandra Schwarcz, MD, MPH, the principal investigator of the study and a member of the SF Department of Public Health AIDS Surveillance Unit.

Schwarcz reported the findings today (July 13) at the XIII International AIDS Conference in Durban, South Africa.

The study included 2,607 persons who were diagnosed with one of the AIDS-defining opportunistic illnesses between 1995-97 and 3,228 persons diagnosed with either an opportunistic illness or low CD4 cell count within the same time period. Researchers analyzed survival trends over time in the first group of patients and looked at how various forms of treatment affected the risk of death in the latter group.

Because San Francisco was one of the first AIDS epidemic centers in North America, disease trends have often been observed first in the city, said Schwarcz. The number of AIDS deaths in San Francisco reached a plateau between 1992-94 and then declined in 1995, as highly active antiretroviral therapy (HAART) was introduced. The years 1996 and 97 saw the greatest (59 percent) decline in AIDS deaths in the city, but between 1997-98 the decline dropped to 30 percent, prompting speculation that the survival benefit associated with HAART might have waned.

To determine whether this was so, researchers at the San Francisco DPH AIDS Surveillance Unit and a UCSF colleague used comprehensive surveillance data to carefully evaluate trends in AIDS survival between 1995-97 and to assess the impact of treatment on the risk of death after AIDS.

The DPH AIDS surveillance registry includes detailed follow-up information on treatment and treatment outcomes, said Schwarcz. Working with this registry, researchers have access to information on the dates and types of AIDS-defining opportunistic illnesses, CD4 test results, and the types and starting dates of antiretroviral therapy and prophylactic medications. Information is collected on patients at the time of diagnosis and is updated annually.

In this study, researchers looked at survival in two ways: by determining the median (midpoint) time of survival for patients and determining the proportion of persons surviving two years after diagnosis. They found that survival increased by both measures in the three-year study period. Median survival was 24 months for persons diagnosed in 1995, 51 months for persons diagnosed in 1996, and could not yet be determined for persons diagnosed in 1997. The proportion of persons surviving two years after diagnosis was 50 percent for those diagnosed in 1995, 69 percent for those diagnosed in 1996, and 70 percent for those diagnosed in 1997.

The researchers also found that use of antiretroviral therapy reduced the risk of death, particularly if it included a protease inhibitor. Patients who received this type of therapy (HAART) after being diagnosed with AIDS, reduced their risk of death by 60 percent, said Schwarcz.

"This finding, combined with other data that predict little negative effect associated with drug resistance and the potential for reduced HIV transmission from persons receiving therapy, supports efforts to expand the use of HAART," said Schwarcz.

The study also determined that the risk of death was increased for persons aged 40 or greater at the time of AIDS diagnosis, for those whose initial AIDS diagnosis included an opportunistic illness, and for both homosexual and heterosexual injection drug users. The risk of death was lower for persons with higher CD4 cell counts at diagnosis.

Co-investigators included Ling Hsu, MPH, San Francisco DPH AIDS Surveillance Unit; Eric Vittinghoff, PhD, UCSF Center for AIDS Prevention Studies; Mitchell H. Katz, MD, director of the San Francisco DPH; and Willi McFarland, MD, PhD, San Francisco DPH HIV Seroepidemiology Unit and UCSF Center for AIDS Prevention Studies.


Story Source:

The above story is based on materials provided by University Of California, San Francisco. Note: Materials may be edited for content and length.


Cite This Page:

University Of California, San Francisco. "San Francisco Study Shows Antiretroviral Treatment Continues To Improve AIDS Survival." ScienceDaily. ScienceDaily, 18 July 2000. <www.sciencedaily.com/releases/2000/07/000717073659.htm>.
University Of California, San Francisco. (2000, July 18). San Francisco Study Shows Antiretroviral Treatment Continues To Improve AIDS Survival. ScienceDaily. Retrieved August 1, 2014 from www.sciencedaily.com/releases/2000/07/000717073659.htm
University Of California, San Francisco. "San Francisco Study Shows Antiretroviral Treatment Continues To Improve AIDS Survival." ScienceDaily. www.sciencedaily.com/releases/2000/07/000717073659.htm (accessed August 1, 2014).

Share This




More Health & Medicine News

Friday, August 1, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Ebola Vaccine Might Be Coming, But Where's It Been?

Ebola Vaccine Might Be Coming, But Where's It Been?

Newsy (Aug. 1, 2014) Health officials are working to fast-track a vaccine — the West-African Ebola outbreak has killed more than 700. But why didn't we already have one? Video provided by Newsy
Powered by NewsLook.com
Study Links Certain Birth Control Pills To Breast Cancer

Study Links Certain Birth Control Pills To Breast Cancer

Newsy (Aug. 1, 2014) Previous studies have made the link between birth control and breast cancer, but the latest makes the link to high-estrogen oral contraceptives. Video provided by Newsy
Powered by NewsLook.com
House Republicans Vote to Sue Obama Over Healthcare Law

House Republicans Vote to Sue Obama Over Healthcare Law

Reuters - US Online Video (July 31, 2014) The Republican-led House of Representatives votes to sue President Obama, accusing him of overstepping his executive authority in making changes to the Affordable Care Act. Mana Rabiee reports. Video provided by Reuters
Powered by NewsLook.com
Uganda on Alert for Ebola but No Confirmed Cases

Uganda on Alert for Ebola but No Confirmed Cases

AFP (July 31, 2014) Uganda's health minister said on Thursday that there are no confirmed cases of Ebola in the country, but that it remained on alert for cases of the deadly virus. Uganda has suffered Ebola outbreaks in the past, most recently in 2012. Duration: 00:59 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins